Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future ...

Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future ...

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Photo: Congratulations to the Regeneron Science Talent Search top three finalists (from left to right) Achyuta Rajaram, with second place winner Thomas Cong and third place awardee Michelle Wei.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

Get the latest Regeneron Pharmaceuticals, Inc. (REGN) stock news and headlines to help you in your trading and investing decisions.

Sojo Industries will use the funds to improve CPG supply chains with fast-deploy modular packaging robotics and blockchain-enabled logistics software ...

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.